Background: Health burdens of hepatocellular carcinoma (HCC) are emerging quickly in the world, including in Taiwan. Surgical resection has been recognized as the first-line treatment for early tumors. This study aimed to investigate the prognostic risk factors for mortality and recurrence rate in Taiwan, which has a high prevalence of chronic viral hepatitis. Methods: A total of 397 HCC patients receiving tumor resection were consecutively examined in central Taiwan from 2008 to 2014. A hospitalbased patient cohort was designed to collect serological markers to further assess liver function. We modified the KaplaneMeier method according to the competing death risks for comparing recurrence and used multivariate Cox proportional hazard regression to adjust for significant risk factors. Results: In addition to advanced fibrosis, tumor size !5 cm was significantly associated with higher mortality within the 5-year period when compared with <5 cm (43.3% vs. 13.2%, p < 0.0001). Patients with tumor size !5 cm also easily progressed to early recurrence within two years when accounting for death as a competing risk (20.1% vs. 10.1%, p ¼ 0.01). Higher AFP levels played a major role in further predicting higher mortality in those patients. We determined that there were a 4.5-fold and 2.2-fold higher mortalities in patients with size !5 cm/AFP !20 ng/mL and with size !5 cm/AFP< 20 ng/mL, respectively, when compared to patients with small tumors. Conclusion: Tumor size !5 cm might be a good predicting factor for death and early recurrence when considering death as a competing risk.
Introduction
With a rapidly increasing incidence rate, hepatocellular carcinoma (HCC) is the sixth most common cancer and the third most common cause of cancer mortality in the world. 1 Most HCCs progress from chronic viral hepatitis (chronic hepatitis B, CHB; chronic hepatitis C, CHC), alcohol intake, Conflicts of interest: The authors declare that they have no conflicts of interest related to the subject matter or materials discussed in this article.aflatoxin exposure, older age and male gender. 1e5 The etiologies appear to differ in an ethnicity-specific manner. 6 All etiologic forms of advanced liver fibrosis may be complicated by tumor formation. 7, 8 One-third of cirrhotic patients will develop HCC 9 by gradually (with 1e8% growth per year). 10 After a diagnosis of HCC, surgical resection, liver transplantation, radiofrequency ablation, transarterial chemoembolization, and targeted molecular therapy are used to treat HCC according to clinical profiles. 1 Resection is the first-line treatment option for patients with early tumors (solitary tumor or very well-preserved liver function), with a 5-year survival rate of 60e80%. 11, 12 However, standard HCC resection in cirrhotic patients leads to a higher mortality rate, contributing to a lower 5-year survival rate of approximately 50e60%. 2, 13 Two major prognostic factors, liver function and tumor characteristics, have been associated with all-cause mortality or recurrence rate after resection. Child-Pugh class has often been used to assess liver function that might be related to late recurrence (>2 years), but not with early recurrence. 14 Regarding tumor characteristics, the main predictors of survival are tumor size, 15e19 tumor number and vascular invasion. 14,20e24 In addition, combined with liver function and other risk factors, poorer differentiation grades at Ishak stage 6 25 and surgical resection margin 1 cm in small tumors 26 have been associated with higher recurrence or mortality or rate.
Despite the known factors related to tumor and liver function that are associated with long-term survival in ethnic and etiologic groups, death occurring before HCC recurrence leads to information censoring and often to overestimation of the recurrence probability. Recently, several studies have reported that death should be regarded as a competing risk event in estimating the recurrence of HCC. 27 The aim of the present study was to investigate the prognostic risk factors for mortality and HCC recurrence rate with consideration of the competing risk in Taiwan.
Methods

Patient eligibility
Between November 2008 and December 2014, a total of 477 patients diagnosed with liver cancer who received surgical resection as first-line therapy in a medical center in central Taiwan were consecutively examined for eligibility. Thirtyeight patients were ineligible to enroll in this study for the following reasons: 5 had cholangiocarcinoma, 17 had combined cholangiocarcinoma and HCC, and 16 had adenocarcinoma or other cancer. Fourteen HCC patients who were not suitable for resection were also excluded. Seventeen surgical deaths within 60 days and 11 patients with HCC occurrence within 90 days were excluded among these remaining 425 patients since it was not appropriate to enroll the patients who died early and had HCC recurrence soon after the operation possibly due to misdiagnosis caused by current medical limitation. Finally, 397 HCC patients with Barcelona Clinic Liver Cancer (BCLC) stage 0 to B receiving tumor resection were enrolled in the study. The flow of participants through the hospital-based study is presented in Fig. 1 .
All patients provided written informed consent. The institutional review board of the Kaohsiung Medical University Hospital approved the protocols, which conformed to the guidelines of the International Conference on Harmonization for Good Clinical Practice. All procedures followed were by the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.
Assessment of serological markers and liver function
After enrollment, serum biochemistries (alanine aminotransferase (ALT), aspartate aminotransferase (AST), alphafetoprotein (AFP), total bilirubin, albumin, creatinine, prothrombin time (PT)/International Normalized Ratio (INR), and complete blood counts (white blood cells, platelets, hemoglobin)) were measured using a systemic multi-autoanalyzer (Technicon SMAC, Technicon Instruments Corp., Tarrytown, NY, USA). Hepatitis B surface antigen (HBsAg) and anti-HCV antibodies were detected using a third-generation, commercially available enzyme-linked immunosorbent assay kit (AxSYM 3.0; Abbott Laboratories, Chicago, IL, USA). Liver function was cautiously evaluated with biochemistry tests and the Child-Pugh classification.
Diagnosis of HCC
The diagnosis of HCC in all patients was assessed using axial imaging [computed tomography (CT) scan with intravenous contrast or magnetic resonance imaging (MRI) with intravenous contrast]. All patients were retrospectively assigned to the various stages according to the classification criteria of the BCLC 28 and the American Joint Committee on Cancer (AJCC), 7th edition TNM staging systems. 29 Liver resection was performed in patients with normal synthetic liver function as assessed by normal serum total bilirubin, albumin and PT (INR).
Assessment of liver histopathology and tumor characteristics
After the operation, specimens were fixed and assessed for tumor characteristics and liver fibrosis by a pathologist. Neoplastic liver tissue, tumor number, largest tumor diameter, differentiated grades and surgical margins were determined. A free surgical margin was defined as a distance of 1 cm between the cut surface and the tumor edge in the resected specimen. In non-neoplastic liver tissue, the degree of hepatic inflammation and fibrosis was assessed with the Ishak fibrosis score as follows: stage 0 (normal liver); stage 1 (fibrosis expansion of a few portal tracts); stage 2 (fibrosis of all portal tracts); stage 3 (fibrosis expansion of most portal areas with occasional portal-to-portal bridging); stage 4 (fibrosis expansion of portal areas with marked bridging); stage 5 (marked bridging with occasional nodules); and stage 6 (established cirrhosis with the tissue entirely composed of nodules).
30e32 In this study, scores of 0e2 represented minimal fibrosis, scores of 3e4 represented moderate fibrosis, and scores of 5e6 represented advanced fibrosis.
Follow-up after tumor resection
All patients were regularly followed up every three months in the first postoperative year and every six months thereafter. Imaging with CT or MRI was obtained for each patient at every follow-up visit, along with blood tests including AFP as the only adjunct to imaging findings. Tumor recurrence was diagnosed as the appearance of a new lesion based on the imaging findings on CT or MRI.
Statistical analysis
The data are expressed as the means ± standard deviation (SD), median/interquartile range (IQR), or n (%), as appropriate. Variables were compared using the chi-square test (or Fisher's exact test when n < 5) for categorical data and Student's t-test (or the nonparametric ManneWhitney U test) for continuous variables. The sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV) and accuracy were calculated according to standard formulas.
The period from the date of the operation to the date of death, last follow-up, or recurrence was recorded for each patient. Patients lost to follow-up or with no death (or no recurrence) were entered as censored data. The cumulative probability of mortality and recurrence were calculated using the KaplaneMeier method, and differences were compared using the log-rank test. The association between clinically relevant variables and mortality or recurrence rate was compared with the estimated hazard ratio and 95% confidence interval using univariate or multivariate Cox proportional-hazard regression. Because death before recurrence was considered a competing risk event, we modified the standard KaplaneMeier method with the cumulative incidence method according to competition for death. 33 Multivariate Cox proportional hazard regression and a subdistribution hazards model 34 with adjustments for significant risk factors for recurrence were also performed. A p value < 0.05 on a two-tailed test was considered significant. Statistical analyses were performed using JMP software version 10.0 (SAS Institute, Inc., Cary, NC, USA) and the R program with the "cmprsk" package. 35, 36 3. Results
Baseline clinical-pathologic characteristics of patients
The baseline clinical characteristics of the 397 HCC patients before operation are shown in Table 1 . There were 289 men and 108 women with a mean age of 63.4 years. Among them, there were 15 (3.8%) with alcohol exposure, 174 (43.8%) with positive HBsAg, 140 (35.2%) with positive anti-HCV and 118 (30.1%) with advanced fibrosis (Ishak 5e6). Additionally, among the 397 enrolled patients, 94.1% were classified as non-LC/Child-Pugh class A and 5.9% as class B. Thirty-four (19.5%) of 174 HBV patients had received anti-HBV treatment, and only 4 (2.9%) of 140 HCV patients had received anti-HCV treatment before and after surgical resection. One-third of HCC patients had a surgical resection margin of more than 1 cm. With regard to tumor factors, the mean maximum tumor size was 4.3 cm. Most patients (327 or 84.5%) had a single tumor, and 184 (46.5%) of them had poorly-differentiated or undifferentiated histology. About 28.8% and 12.3% of the patients had BCLC stage B and AJCC stage 3e4, respectively.
HCC patient cohort in follow-up
Among the 397 HCC patients who were followed up, the median follow-up period was 22 months (range 0e63), 31 (7.8%) patients died after recurrence, 13 (3.3%) patients had HCC recurrence, 34 (8.6%) patients died, and 319 (80.3%) remained alive at last visit (Fig. 1) . Among the 44 HCC recurrence patients, 41 (95.3%) had recurrence within one year. Therefore, the 1-, 3-and 5-year cumulative all-cause mortalities (5.6%, 20.8%, and 32.0%, respectively), liver-related mortalities (3.3%, 14.4%, and 23.0%, respectively), and recurrence rates (12.5%, 13.4%, and 13.4%, respectively) are presented (Fig. 2) .
Factors associated with death in univariate and multivariate survival analyses
In addition to known advanced fibrosis significantly associated with all-cause mortality (adjusted p value ¼ 0.002), the univariate and multivariate Cox proportion hazard analyses demonstrated that patients with larger tumor diameter and Ishak score of 5e6 had a higher rate of mortality (crude p value ¼ 0.0007 and 0.003, respectively, and adjusted p values ¼ 0.020 and 0.002, respectively) ( Table 2) . For clinical application, we used the integer fittest value by the ROC curve for tumor size to predict those long-term events. We found that a tumor diameter of an integer of 5 cm, with higher increased accuracy and better negative predictive value, was a better cutoff value than others (Supplemental Table 1 ). The cumulative all-cause mortality rates at 1, 3 and 5 years were 1.8%, 9.4% and 13.2%, respectively, for patients with tumor size <5 cm and 9.5%, 18.7%, and 43.3%, respectively, for patients with tumor size !5 cm ( p value < 0.0001) (Fig. 3) . AFP was significantly associated with mortality in patients with tumor size !5 cm (log-rank p value ¼ 0.04), but not in patients with tumor size < 5 cm (log-rank p value ¼ 0.41) (Fig. 4A ). Among patients with tumor size !5 cm, AFP >20 ng/mL was a significant factor for predicting mortality in the multivariate survival analysis (adjusted p value ¼ 0.01) ( Table 3 ). Fig. 4B shows that the cumulative mortality within 4 years was 21.1% for patients with largest tumor size <5 cm, while it was 51.8% and 64.4% in those with tumor size !5 cm/AFP <20 ng/mL and size !5 cm/AFP !20 ng/mL, respectively (HR ¼ 2.16 and p value ¼ 0.03; HR ¼ 4.48 and p value < 0.0001, respectively). In this study, 34 (52.3%) of 65 patients died from causes which were not related to HCC recurrence. There were 3 non liver-related deaths (including 1 with multiple organ failure, 1 with brain infarction, 1 with unknown cause), 22 liver-related deaths (including 3 with hepatic failure, 1 with liver abscess, and the remainder with HCC metastasis), 3 with non-HCC cancer deaths, and 6 with unclear cause of deaths.
Factors associated with recurrence in univariate and multivariate survival analyses
Many patients might die before HCC recurrence. Therefore, we used two approaches to account for death as a competing risk event to calculate the cumulative incidences of recurrence. Table 2 shows the death-adjusted cumulative recurrence rate and hazard ratio by significant factors in univariate and multivariate survival analyses. Large tumor size was an important independent risk factor for HCC recurrence (adjusted p value ¼ 0.02). Poorly differentiated tumor was also an independent factor associated with HCC recurrence (adjusted p value ¼ 0.05) ( Table 2) . Fig. 2 . Cumulative all-cause mortality, liver-related mortality and recurrence probability estimated by the KaplaneMeier approach (n ¼ 397). The HCC recurrence rate was also significantly higher for patients with tumor size !5 cm (Supplemental Table 1 ). The crude (death-adjusted) cumulative recurrence rates at 1, 2, and 3 years were 9.6% (9.5%), 10.2% (10.1%), and 10.2% (10.1%), respectively, for patients with a tumor size < 5 cm and 20.3% (19.4%), 22.1% (20.1%) and 22.1 (20.1%), respectively, for patients with a tumor size ! 5 cm, (crude p value ¼ 0.005 and adjusted p value ¼ 0.01) (Fig. 3) . No matter whether in patients with tumor size !5 cm or size <5 cm, no other risk factors were associated with HCC recurrence (data not shown).
Discussion
In the present study, we enrolled a large hospital-based patient cohort under a follow-up schedule to demonstrate that a tumor diameter of 5 cm was the best cutoff for predicting HCC mortality and recurrence rate in Taiwanese patients. In addition to advanced fibrosis, tumor size !5 cm was significantly associated with higher mortality the 5-year period (43.3% vs. 13.2%, p value < 0.0001). Patients with tumor size !5 cm also easily progressed to early recurrence within 2 years when precisely accounting for death as a competing risk Fig. 3 . Cumulative all-cause mortality and recurrence rate without (crude)/with (adjusted) accounting for a competing risk event stratified by tumor size. Fig. 4 . Cumulative mortality of patients stratified by 5 cm of tumor size and 20 ng/mL of AFP using the KaplaneMeier method and compared using a log rank test a Abbreviations: Tsize, the largest tumor diameter; AFP, alpha-fetoprotein. event (20.1% vs. 10.1%, p value ¼ 0.01). Of note, we also showed that among patients with tumor size !5 cm, higher AFP played an important role in further predicting higher mortality. We found 4.5-fold and a 2.2-fold higher mortalities in patients with tumor size !5 cm/AFP !20 ng/mL and with size !5 cm/AFP <20 ng/mL, respectively, when compared to those patients with size <5 cm/AFP <20 ng/mL.
Our previous study reported that, Taiwanese patients with BCLC early HCC (single tumor, size 3 cm, and Child-Pugh class A) receiving liver resection, the cumulative 1-, 3-, and 5-year cumulative mortality rates were 0%, 3%, and 15.4%. 37 In the present study, we further found there was a significant difference between small and large tumor size for 5-year allcause mortality, respectively (13.2% in size < 5 cm vs. 43.3% in size !5 cm and 32.0% of total population) in Taiwan. In a Japanese nationwide study of over 10,000 HCC patients, the 5-year all-cause mortality of all patients was up to 50%, while for patients with HCC 2 cm, mortality was 34%, compared with 48% for tumors 2e5 cm and 63% for tumors !5 cm. 18 This difference might be due to the high percentage of our patients with solitary tumors (more than 80%), twothirds of which were small tumors. Our patients had a high rate of early recurrence, 95.3% recurrence within one year, and most patients recurred at sites different from the surgical sites. In the present study, we focused on the early-recurrence patients who had larger tumor size (mean size: 5.9 cm) and poorer differentiation (61.4% with poor-differentiated), and these might induce early recurrence within 2 years after surgery. In fact, the 5-year recurrence rate after tumor resection was very low (10.1% for size < 5 cm, 20.1% for size ! 5 cm and 13.4% of total population) compared with the rate reported by a Japanese study of 616 patients with solitary tumors. 16 The 5-year recurrence rate for HCC < 5 cm was 68%, which was significantly lower than those for HCC 5e10 cm (74%) and HCC > 10 cm (76%). 16 In our previous study, after completion of pegylated interferon and ribavirin therapy, 43 (41.0%) patients developed cases of HCC recurrence, 24 (55.8%) of which recurred within six months. 38 In this study, the recurrence within one year did not exclude possible clinically undetected tiny HCCs before liver resection. Our results suggest that if patients survive early recurrence, the low recurrence rate of HCC in Taiwanese patients with BCLC stage 0 to B should be noted as encouraging of the use of surgical therapy. In particular, patients with tumor size less than 5 cm will get more benefit.
In addition to tumor factors associated with HCC death and recurrence, an etiological factor might exist that is associated with HCC progress, although there was no such significant finding in our study. A previous report involving Japanese HCC patients who had tumor resection showed an association between viral status and survival only in Child-Pugh class A patients. The 3-, 5-and 10-year recurrence rates for HC-HCC (60%, 76% and 88%, respectively) were significantly higher than those for HB-HCC (43%, 46% and 72%, respectively). 39 Patients with HBV/HCV co-infections had a 2-fold higher death rate compared with virus-free patients. 40 In our study, we have reported, along with the higher prevalence of HCV infection (35%) in Taiwanese HCC patients, the minimal role of HBV or HCV infection among patients with BCLC 0 to B receiving liver resection. In specific subgroups, the risk factors for predicting death and early or late recurrence were different. In two studies involving HBV-related HCC, 14, 25 tumor factors (multinodularity, macroscopic venous invasion, AFP > 20 ng/ ml, and margin 1 cm) were associated with early ( 2 years) HCC recurrence. On the other hand, high viral loads (HBV DNA level > 10 6 copies/ml) and hepatic inflammatory activity (Ishak stage > 6, multinodularity) were associated with late recurrence. 14 Ishak stage 6 was independently associated with the higher mortality and recurrence rates. In patients with Ishak stage 1e5, tumor size was associated with mortality, and tumor size, HAI grade, and AFP >20 ng/ml were associated with recurrence rate, while poorly differentiated histology and tumor size were associated with higher mortality, and tumor size was associated with recurrence in patients with Ishak stage 6. 25 Our study showed the important role of tumor size and advanced fibrosis in predicting mortality and the role of tumor size and histopathological differentiation in predicting tumor recurrence in clinical practice.
In the literature, there are inconsistent cut-off values in tumor diameter, such as 2, 3, 5, 8 and 10 cm, as criteria for therapies in etiologic and ethnic HCC patients. In Asian studies, including those in Taiwan and Japan, 2e5 cm tumor size has often been adopted, 16e19 compared to 8e10 cm in European studies. 15 Three studies that focused on large tumors (!10 cm) 22e24 concluded that AFP ! 1000 ng/mL, multiple tumor nodules, the presence of major vascular invasion 22 and the presence of cirrhosis were also significant predictors of mortality. 23 In contrast, patients with solitary HCC without portal vein tumor thrombosis showed a favorable surgical outcome for larger tumors. 24 Our study and previous studies have shown that increasing tumor size correlated significantly with higher mortality, 17, 19 and that 5 cm may be considered the cut-off point for HCC prediction in Taiwanese patients.
This study has some limitations. First, although we followed the patients for five years, most HCC patients had a recurrence within one year after tumor resection; therefore, we did not have enough information for predicting longer-term recurrence. Second, macro-and micro-vascular invasion have been reported as important risk factors for predicting death or recurrence, 14, 20, 21, 23 but only one-fourth of our enrolled patients had this factor, which makes it hard to conduct a future analysis using data from the present study. Third, we classified etiological factors as alcohol exposure, CHB and CHC. However, we did not identify actual alcohol levels, viral loads or viral genotypes that might influence the progress of recurrence and death in a retrospective study design. 20, 21, 23 We have demonstrated that tumor size !5 cm might be a good predicting factor for mortality and early recurrence when considering death as a competing risk. In patients with tumor size !5 cm, higher AFP levels were associated with mortality, which indicated the critical value of follow-up of AFP in specific patient groups.
